Chongtu Yang

Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective

EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma

Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center

Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination